Alexa-AChR Conjugate Flow Cytometry for Myasthenia Gravis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Myasthenia Gravis (MG) are inadequate, as they rely on serum antibody tests that do not correlate with disease severity and require specialized facilities, and existing treatments have deleterious side effects, necessitating a more specific and reliable diagnostic tool and therapeutic approach.
Innovation Solution
Development of a novel reagent and kit using Alexa-AChR conjugates for flow cytometry to detect and quantify AChR-reactive B cells in patient blood samples, allowing for rapid assessment of MG severity and monitoring of treatment efficacy in any hospital setting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum antibody tests are used for diagnosing MG, then the diagnostic process can be performed in specialized facilities, but the antibody titers detected do not correlate with disease severity
Solution Approach 1:
The patent uses flow cytometry as an intermediary technology to detect AChR-reactive B cells directly in patient blood samples. This mediator approach allows detection of the actual pathogenic cells rather than relying on serum antibody titers, providing better correlation with disease severity while enabling performance in standard hospital laboratories equipped with flow cytometers.
Solution Approach 2:
The patent replaces the traditional serum-based immunoassay system with a cellular analysis system using flow cytometry. This substitution shifts from measuring soluble antibodies in serum to directly detecting and quantifying AChR-reactive B cells in blood, providing more accurate disease severity assessment.
2Reliability
If non-specific immunosuppressive drugs are used to treat MG, then the overall immune response is suppressed, but deleterious side effects occur
Solution Approach 1:
The patent enables antigen-specific immunotherapy by targeting AChR-reactive B cells specifically. This local quality approach allows suppression of the specific pathogenic immune response against AChR while preserving the overall immune system function, avoiding the broad suppression and side effects of non-specific immunosuppressive drugs.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific immune suppression to specific targeting of AChR-reactive B cells. By using flow cytometry to identify and enable targeted therapy against these specific cells, the treatment achieves effectiveness while minimizing harmful side effects through parameter-specific intervention.
3Measurement precision
If flow cytometry with Alexa-AChR conjugates is used to detect AChR-reactive B cells, then precise detection and quantification is achieved, but the method requires new reagents and protocols
Solution Approach 1:
The patent uses Alexa-fluor conjugated AChR as a copy or surrogate for the native AChR antigen. This fluorescently labeled copy allows direct binding to AChR-reactive B cells and enables detection through flow cytometry, achieving precise measurement while using a well-established technique platform.
Solution Approach 2:
The patent changes the detection parameter by introducing fluorescent labeling to AChR. This parameter change allows the use of flow cytometry, a widely available technology, to detect and quantify AChR-reactive B cells, balancing measurement precision with practical implementability in standard hospital settings.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables precise detection of AChR-reactive B cells, providing a reliable marker for MG severity and facilitating effective treatment monitoring, overcoming the limitations of existing diagnostic tests and treatments.
Implementation Method 1
contacting a sample comprising B cells with an acetylcholine receptor (AChR) conjugate; determining a level of AChR binding B cells
Data Source
AI summary
Disclosed are methods, compositions, and diagnostic kits for detecting acetylcholine receptor (AchR) autoreactive immune cells in a subject. The methods comprise detecting the binding of AChR-conjugate to penpheral blood AChR-specific B cells for diagnosing autoimmune disorders, including Myasthenia gravis (MG), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). More specifically, the detection is achieved by using flow cytometric assay with Alexa-conjugated AchR.